Skip to content
  • Home
  • Signal News
  • Biopharma Digest
    • Market Access Intelligence
    • Rare Disease Gene Therapy
    • Oncology
  • Week in Review
    • GLP-1 Competitive Market
    • NeuroMarket Pulse
      • Neurology Regulatory Interactive Calendar
    • Manufacturing Intelligence
  • Contact

Pharminent

 Posted in Commercial

Senju launches first-in-class dry eye disease drug in Japan

 April 10, 2026

Pharmaphorum

Senju has launched a new drug for dry eye disease (DED) in Japan, Avarept, the first drug in the TRPV1 antagonist class to reach the market.

CommercialOphthalmologyRead full story

Post navigation

GSK again pulls application for leucovorin, touted by FDA as potential autism treatment →
← With oral obesity race underway, all eyes are on Lilly’s Foundayo launch

Categories

© 2026 Pharminent. All rights reserved.

Design by ThemesDNA.com